{"id":1602,"date":"2025-09-02T15:44:33","date_gmt":"2025-09-02T02:44:33","guid":{"rendered":"https:\/\/blis.co.nz\/?p=1602"},"modified":"2025-09-03T14:00:22","modified_gmt":"2025-09-03T01:00:22","slug":"blism18-for-braces","status":"publish","type":"post","link":"https:\/\/blis.co.nz\/white-papers\/blism18-for-braces\/","title":{"rendered":"WHITEPAPER: ORAL PROBIOTICS FOR BRACES: REDUCING HALITOSIS WITH BLIS M18\u2122"},"content":{"rendered":"\n

<\/p>\n\n\n\n

Clinical data reveals how a targeted oral probiotic can deliver a breakthrough solution to a common problem\u2014bad breath during orthodontic treatment.<\/strong><\/p>\n\n\n\n

Halitosis is an often-overlooked yet highly disruptive side effect for people wearing braces. With up to 50% of the global population undergoing orthodontic treatment at some stage in life, there’s a growing demand for non-invasive, scientifically credible solutions that go beyond traditional hygiene methods.<\/p>\n\n\n\n

In this whitepaper, BLIS Technologies presents in-vitro and clinical trial evidence<\/strong> demonstrating how BLIS M18\u2122<\/strong>, a precision probiotic strain of Streptococcus salivarius<\/em>, effectively reduces volatile sulphur compounds (VSCs)\u2014the primary cause of bad breath in orthodontic patients.<\/p>\n\n\n\n

Whether you’re developing new product formats or looking to differentiate with clinically validated oral care innovations, this is essential reading for formulators, brand leaders, and healthcare partners.<\/p>\n\n\n\n

What You\u2019ll Learn:<\/strong><\/h6>\n\n\n\n
    \n
  • The microbial mechanism behind halitosis in braces wearers<\/li>\n\n\n\n
  • Clinical study results showing sustained reduction in VSCs post-intervention<\/li>\n\n\n\n
  • How BLIS M18\u2122 complements oral hygiene by targeting the root microbial cause<\/li>\n\n\n\n
  • Opportunities for product innovation using a science-led, strain-specific probiotic

    <\/li>\n<\/ul>\n\n\n\n